Brief: Adocia And Tonghua Dongbao Announce Final Dosing In Phase 3 Clinical Study Of Biochaperone® Lispro
12/12/2024 17:57
Dec 12 (Reuters) - Adocia SA ADOC.PA :
* ADOCIA AND TONGHUA DONGBAO ANNOUNCE THE FINAL DOSING IN A
PHASE
3 CLINICAL STUDY OF BIOCHAPERONE® LISPRO, MILESTONE ASSOCIATED
WITH A $10 MILLION PAYMENT
* ADOCIA SA - PHASE 3 TOPLINE RESULTS EXPECTED IN H1 2025
* ADOCIA SA - SECOND STUDY IN TYPE 1 DIABETES NEARING END OF
TREATMENT, EXPECTED TO BE IN EARLY 2025
Source text: ID:nBw3Ps00Ja
Further company coverage: ADOC.PA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Adocia SA
See all newsBrief: Adocia And Vester Finance Sign Shareholder Loan Agreement
Brief: Adocia Sees Challenges With GLP-1, Amylin & Other Metabolic Peptides
Brief: Adocia H1 Operating Income EUR -8.932 Million
Brief: Adocia, Tonghua Dongbao Reports Positive Phase 3 Results For Ultra-Rapid Insulin In T2D
Brief: Adocia And Tonghua Dongbao Announce Final Dosing In Phase 3 Clinical Study Of Biochaperone® Lispro